MHRA is investigating unlicensed Botox

The enforcement signal

On 15 July 2026, the Medicines and Healthcare products Regulatory Agency published two coordinated announcements. The first was a public news release and the second a formal Drug Safety Update for healthcare professionals. Between them, they contain two distinct regulatory actions that should not be collapsed into a single headline.

The MHRA is strengthening the wording on the risk of iatrogenic botulism in the Summary of Product Characteristics and Patient Information Leaflet for all UK-authorised botulinum toxin type A products. That is ordinary pharmacovigilance: a recognised but rare risk is being communicated more clearly.

At the same time, the MHRA's Criminal Enforcement Unit has launched a number of investigations linked to unlicensed botulinum toxin products after a spike in hospital admissions in 2025. That is not a routine label update. It is an active criminal enforcement operation.

Two issues, not one

The distinction matters for every clinic that uses botulinum toxin products. One issue is about authorised medicines and clearer warnings on a recognised but rare risk. The other is about products outside the regulated supply chain that may never have met UK quality and safety standards — and that are now the subject of criminal investigations.

Both issues affect patient safety. But they call for different responses from clinics: one requires updating patient information and consent materials; the other requires verifying that every product in the supply chain is UK-authorised and traceable.

What the MHRA actually warned

The Drug Safety Update provides the clinical details. The key points for practitioners are:

• Symptom timing: Symptoms of iatrogenic botulism typically develop between four and eight days after treatment, but can take up to four weeks to appear.
• Warning signs: Symptoms include difficulty swallowing or speaking, difficulty breathing or shallow breathing, blurred or double vision, drooping eyelids, muscle weakness, and severe tiredness or fatigue.
• Emergency action: Suspected botulism is a medical emergency. The MHRA advises that patients with suspected iatrogenic botulism require immediate specialist assessment and treatment at a hospital emergency department.
• Higher-risk contexts: The MHRA identifies several factors that increase risk, including underlying neuromuscular disorders, higher doses, off-label use, unapproved injection sites, and counterfeit or unauthorised products.

The MHRA asks healthcare professionals, patients, and caregivers to report suspected adverse reactions through the Yellow Card scheme. This reporting applies regardless of whether the product was authorised or unauthorised — Yellow Card data is a key source for both pharmacovigilance and enforcement intelligence.

The evidence trail clinics should hold

The MHRA's publications do not constitute new legal requirements for record-keeping. But the enforcement signal is clear: when investigations into unlicensed products are active, clinics should be able to demonstrate that their supply chain is legitimate. The following evidence is suggested by the regulator's published warning, not by any new legislation:

• Product identity and authorisation status: The exact product name, manufacturer, and UK marketing authorisation number. Authorised botulinum toxin products can be checked against the MHRA's product database.
• Supplier and batch traceability: Purchase records, batch numbers, and supply chain documentation that establish the product came from a legitimate UK wholesaler or manufacturer.
• Prescriber and administrator identification: Records of who prescribed and who administered the product, including their professional registration details where applicable.
• Patient information and consent: Records reflecting the updated warnings about iatrogenic botulism risk, including the symptom window and emergency action advice.
• Escalation routes: Documented awareness of the Yellow Card reporting route and internal escalation procedures for suspected adverse reactions.
• Regulator registration: Confirmation that the practitioner and premises are registered with the appropriate healthcare regulator — for example, the General Medical Council, Nursing and Midwifery Council, or General Dental Council. Registration alone does not prove product legitimacy or practitioner competence. The MHRA publications do not say whether professional-registration status forms part of its current investigations.

What remains unknown

The MHRA has not publicly identified investigation targets or announced outcomes in either of its 15 July publications. That is consistent with standard practice for active criminal investigations. The following questions remain open:

• What specific unlicensed products or suppliers are under investigation?
• How many investigations has the Criminal Enforcement Unit opened?
• What offences, if any, are suspected under the Human Medicines Regulations 2012 or other legislation?
• Have any clinics or practitioners been linked to the hospital admissions that triggered the investigations?
• What enforcement outcomes — prosecutions, warning letters, seizure actions — will follow?

It is important to report these facts plainly. The MHRA has not alleged wrongdoing by any named clinic or practitioner. Separating confirmed facts from open questions is how responsible enforcement journalism maintains its credibility.

What to watch next

The MHRA's Criminal Enforcement Unit publishes outcomes of its investigations when they reach a conclusion. Clinics should monitor:

• MHRA enforcement news releases for investigation outcomes and safety alerts
• Further Drug Safety Updates for any changes to product information or clinical guidance
• Regulatory cross-references: the GPhC, ASA, and CQC may all have enforcement interests where unlicensed product use intersects with their remits

This is a developing enforcement story. The clinical safety update has been published, the investigations are active, and the information landscape will change as the MHRA completes its work. We're tracking this.